Illumina, Inc.
Financials
Valuation Metrics
Illumina, Inc.'s Market Cap is $34.27B. At end of 2025 it was $20.07B. Ranked #406 of 3,118 in US market (top 13%), #118 of 1,474 on NASDAQ (top 8%), #25 of 203 in Health Care Equipment & Services (top 12%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $34.27B | US#406/3,118 Sec#25/203 |
| Revenue | $4.49B | US#944/3,118 Sec#56/203 |
| Net Income | $825M | US#618/3,118 Sec#36/203 |
| Total Assets | $6.65B | US#1,242/3,118 Sec#55/203 |
| Net Assets | $2.84B | US#1,011/3,118 Sec#53/203 |
| Employees | 8,600 | US#935/3,118 Sec#71/203 |
| Value | ||
| P/E | 41.54x | US#1,842/3,118 Sec#90/203 |
| P/B | 12.07x | US#2,690/3,118 Sec#176/203 |
| P/S | 7.63x | US#2,602/3,118 Sec#173/203 |
| EV/EBITDA | 26.23x | US#2,151/3,118 Sec#109/203 |
| FCF Yield | 2.74% | US#1,905/3,118 Sec#111/203 |
| Profitability | ||
| ROE | 29.07% | US#319/3,118 Sec#15/203 |
| ROA | 12.41% | US#334/3,118 Sec#18/203 |
| Op. Margin | 20.97% | US#838/3,118 Sec#25/203 |
| Revenue Growth | 4.93% | US#1,780/3,118 Sec#131/203 |
| Earnings Growth | -34.42% | US#1,630/3,118 Sec#87/203 |
| Financial Health | ||
| Debt Ratio | 134.32% | US#1,377/3,118 Sec#127/203 |
| Total Debt | $2.53B | US#1,026/3,118 Sec#48/203 |
| FCF | $939M | US#612/3,118 Sec#37/203 |
| Cash | $1.04B | US#661/3,118 Sec#37/203 |
| Current Ratio | 1.80x | US#1,370/3,118 Sec#121/203 |
| Net Debt/EBITDA | 1.09x | US#1,005/3,118 Sec#58/203 |
| Performance | ||
| 1Y Return | 83.33% | US#67/3,118 Sec#12/203 |
| 1M Return | -17.05% | US#2,611/3,118 Sec#184/203 |
| From 52W High | -26.79% | US#1,665/3,118 Sec#131/203 |
| 1Y MDD | -25.66% | US#985/3,118 Sec#35/203 |
| Trading | ||
| Volume | 2,602,378 shares | US#411/3,118 Sec#19/203 |
| Trading Value | $595M | US#95/3,118 Sec#3/203 |
| Per Share | ||
| EPS | $5.45 | US#620/3,118 Sec#38/203 |
| BPS | $18.76 | US#1,298/3,118 Sec#73/203 |
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.